[Glucocorticoid-induced osteoporosis-Focus treatment (part 2)].
Glukokortikoid-induzierte Osteoporose – Fokus Therapie (Teil 2).
Antiresorptive treatment
Bisphosphonates
Contraindications
Osteoanabolic treatment
Vertebral fracture
Journal
Zeitschrift fur Rheumatologie
ISSN: 1435-1250
Titre abrégé: Z Rheumatol
Pays: Germany
ID NLM: 0414162
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
accepted:
27
10
2021
pubmed:
11
1
2022
medline:
8
3
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
The following substances are approved for the treatment of glucocorticoid-induced osteoporosis: the oral bisphosphonates alendronate and risedronate, the intravenous bisphosphonate zoledronate, the RANKL antibody denosumab as antiresorptive substances and teriparatide as osteoanabolic substance. In comparison to placebo a reduction of vertebral fractures is proven for all mentioned substances. Thereby, teriparatide is more effective than alendronate and risedronate with respect to the reduction of vertebral fractures. The severity of osteoporosis, especially the presence of osteoporotic fractures, the approach of treatment (preventive or curative) and contraindications are factors that are important for the differentiated application of the mentioned substances. Furthermore, it must be noted that the effect of osteoanabolic treatment must be stabilized by a subsequent antiresorptive treatment and that after termination of antiresorptive treatment with denosumab a temporary bisphosphonate treatment is required to prevent a rebound phenomenon. Für die Behandlung der Glukokortikoid-induzierten Osteoporose sind folgende Substanzen zugelassen: die oralen Bisphosphonate Alendronat und Risedronat, das intravenöse Bisphosphonat Zoledronat, der RANKL-Antikörper Denosumab als antiresorptiv wirksame Substanzen und Teriparatid als osteoanabole Substanz. Im Vergleich zu Placebo ist für alle genannten Substanzen eine Reduktion vertebraler Frakturen belegt. Dabei ist Teriparatid im Hinblick auf die Reduktion vertebraler Frakturen wirksamer als Alendronat und Risedronat. Schweregrad der Osteoporose, insbesondere das Vorliegen osteoporotischer Frakturen, der Ansatz der Therapie (präventiv oder kurativ) und das Vorliegen von Kontraindikationen sind Faktoren, die für den differenzierten Einsatz der genannten Substanzen von Bedeutung sind. Ferner muss beachtet werden, dass der Effekt einer osteoanabolen Therapie mit einer sich anschließenden antiresorptiven Therapie stabilisiert werden muss und dass nach Beendigung einer antiresorptiven Therapie mit Denosumab eine zeitlich befristete Bisphosphonattherapie erforderlich ist, um ein Reboundphänomen zu verhindern.
Autres résumés
Type: Publisher
(ger)
Für die Behandlung der Glukokortikoid-induzierten Osteoporose sind folgende Substanzen zugelassen: die oralen Bisphosphonate Alendronat und Risedronat, das intravenöse Bisphosphonat Zoledronat, der RANKL-Antikörper Denosumab als antiresorptiv wirksame Substanzen und Teriparatid als osteoanabole Substanz. Im Vergleich zu Placebo ist für alle genannten Substanzen eine Reduktion vertebraler Frakturen belegt. Dabei ist Teriparatid im Hinblick auf die Reduktion vertebraler Frakturen wirksamer als Alendronat und Risedronat. Schweregrad der Osteoporose, insbesondere das Vorliegen osteoporotischer Frakturen, der Ansatz der Therapie (präventiv oder kurativ) und das Vorliegen von Kontraindikationen sind Faktoren, die für den differenzierten Einsatz der genannten Substanzen von Bedeutung sind. Ferner muss beachtet werden, dass der Effekt einer osteoanabolen Therapie mit einer sich anschließenden antiresorptiven Therapie stabilisiert werden muss und dass nach Beendigung einer antiresorptiven Therapie mit Denosumab eine zeitlich befristete Bisphosphonattherapie erforderlich ist, um ein Reboundphänomen zu verhindern.
Identifiants
pubmed: 35006381
doi: 10.1007/s00393-021-01128-7
pii: 10.1007/s00393-021-01128-7
doi:
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Glucocorticoids
0
Teriparatide
10T9CSU89I
Types de publication
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
125-133Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Saag KG, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292–299
doi: 10.1056/NEJM199807303390502
Adachi JD, Saag KG, Delmas PD et al (2001) Two-Year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211
doi: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W
Yilmaz L, Ozoran K, Gündüz OH et al (2001) Alendronate in rheumatoid arthritis patients with methotrexate and glucocorticoids. Rheumatol Int 20:65–69
doi: 10.1007/s002960000080
De Nijs RNJ, Jacobs JWG, Lems WF et al (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355:675–684
doi: 10.1056/NEJMoa053569
Stoch SA, Saag KG, Greenwald M et al (2009) Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 36:1705–1714
doi: 10.3899/jrheum.081207
Cohen S, Levy RM, Keller M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309–2318
doi: 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K
Eastell R, Devogelaer JP, Peel NF et al (2000) Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11:331–337
doi: 10.1007/s001980070122
Reid DM, Hughes RA, Laan RF et al (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006–1013
doi: 10.1359/jbmr.2000.15.6.1006
Reid DM, Adami S, Devogelaer JP et al (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69:242–247
doi: 10.1007/s00223-001-1060-8
Reid DM, Devogelaer JP, Saag K et al (2009) HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomized controlled trial. Lancet 373:1253–1263
doi: 10.1016/S0140-6736(09)60250-6
Sambrook PN, Roux C, Devogalaer JP et al (2012) Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone 50:289–295
doi: 10.1016/j.bone.2011.10.024
Saag KG, Pannaccciulli N, Geusens P et al (2019) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial. Arthritis Rheumatol 71:1174–1184
doi: 10.1002/art.40874
Iseri K, Iyoda M, Watanabe M et al (2018) The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: a randomized, controlled trial. PLoS ONE 13:e193846
doi: 10.1371/journal.pone.0193846
Petranova T, Sheytanov I, Monov S et al (2014) Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment. Biotechnol Biotechnol Equip 28:1127–1137
doi: 10.1080/13102818.2014.967827
Iwamoto N, Okamoto M, Tsuji S et al (2019) Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs. J Bone Miner Metab 37:554–562
doi: 10.1007/s00774-018-0955-7
Mok CC, Ho LY, Ma KM (2015) Switching of oral bisphosphontes to denosumab in chronic glucocorticoid users: a 12 month randomized controlled trial. Bone 75:222–228
doi: 10.1016/j.bone.2015.03.002
Suzuki T, Nakamura Y, Kato H (2018) Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis. Mod Rheumatol 28:885–889
doi: 10.1080/14397595.2017.1416919
Yamaguchi Y, Morita T, Kumanogoh A (2020) The therapeutic efficacy of denosumab for the loss bone mineral density in glucocorticoid-induced osteoporosis. Rheumatol Adv Pract 4:rkaa8
doi: 10.1093/rap/rkaa008
Saag KG, Shane E, Boonen S et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039
doi: 10.1056/NEJMoa071408
Saag KG, Zanchetta JR, Devogelaer JP et al (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double blind, controlled trial. Arthritis Rheum 60:3346–3355
doi: 10.1002/art.24879
Langdahl BL, Marin F, Shane E et al (2009) Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis. An analysis by gender and menopausal status. Osteoporos Int 20:2095–2104
doi: 10.1007/s00198-009-0917-y
Glüer CC, Marin F, Ringe JD et al (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPS trial. J Bone Miner Res 38:1355–1368
doi: 10.1002/jbmr.1870
Karras D, Stoykov I, Lems WF et al (2012) Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3‑year results from the EFOS. J Rheumatol 39:600–609
doi: 10.3899/jrheum.110947
Deng J, Silver Z, Huang E et al (2020) Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis. Baillieres Clin Rheumatol. https://doi.org/10.1093/rheumatology/keaa228
doi: 10.1093/rheumatology/keaa228
Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis update. Curr Opin Rheumatol 31:388–393
doi: 10.1097/BOR.0000000000000608
Taylor AD, Saag KG (2019) Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy. CE 14:41–50
doi: 10.2147/CE.S172820
Kasperk HC (2020) Zweckmäßige Diagnostik und medikamentöse Therapie der Osteoporose. Arzneiverordn Prax 47:26–37
Lespessailles E, Chapurlat R (2020) High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first. Osteoporos Int 31:1829–1834
doi: 10.1007/s00198-020-05568-w
Langdahl BL, Silverman S, Fujiwara S et al (2018) Real world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: integrated analysis of 4 prospective observational studies. Bone 116:58–66
doi: 10.1016/j.bone.2018.07.013
Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 12:198–202
doi: 10.1002/jbmr.3051
Lewiecki EM (2020) Romosozumab, clinical trials, and real-world care of patients with osteoporosis. Ann Transl Med. https://doi.org/10.21037/atm.2020.03.196
doi: 10.21037/atm.2020.03.196
pubmed: 32953774
pmcid: 7475409
Cummings SR, Ferrari S, Eastell R et al (2018) Vertrebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trail and its extension. J Bone Miner Res 33:190–198
doi: 10.1002/jbmr.3337
Tsourdi E, Zillikens MC, Meier C et al (2021) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 106:264–281
doi: 10.1210/clinem/dgaa756
Kahn AA, Morrison A, Hanley DA et al (2015) Diagnosis and mangement of osteonecrosis of the jaw: a systematic review and internationel consensus. J Bone Miner Res 30:3–23
doi: 10.1002/jbmr.2405
Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737
doi: 10.1056/NEJMoa1010650
Lehmann G, Pfeil A, Oelzner P et al (2020) Renale Osteodystrophie. Akt Rheumatol 45:180–186
doi: 10.1055/a-1104-5161
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7:1–59
doi: 10.1016/j.kisu.2017.04.001
Eguia A, Bagan L, Cardona F (2020) Review and update on drugs related to the development of osteonecrosis of the jaw. Met Oral Patol Oral Cir Bucal 25:71–83
doi: 10.4317/medoral.23191
LDDDDWOG (2017) Prophylaxe, Diagnostik und Therapie der Osteoporose. https://www.awmf.org/upload/xszleitlinien/283-001IS3Osteoporose-Prophylaxe-Diagnostik-Therapie